Online inquiry

IVTScrip™ mRNA-Anti-ICOS, GSK-3359609(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ7948MR)

This product GTTS-WQ7948MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets ICOS gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Humanized
RefSeq NM_012092.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 29851
UniProt ID Q9Y6W8
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ICOS, GSK-3359609(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ7948MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15001MR IVTScrip™ mRNA-Anti-CD19, SJ25C1 scFv-28Z CAR(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA SJ25C1 scFv-28Z CAR
GTTS-WQ7572MR IVTScrip™ mRNA-Anti-CSF3R, G-CSF(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA G-CSF
GTTS-WQ8790MR IVTScrip™ mRNA-Anti-PCSK9, IBI-306(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA IBI-306
GTTS-WQ4449MR IVTScrip™ mRNA-Anti-CTLA4, BMS-734016(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BMS-734016
GTTS-WQ15051MR IVTScrip™ mRNA-Anti-CD47, SRF-231(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA SRF-231
GTTS-WQ7426MR IVTScrip™ mRNA-Anti-EGFR, GA201(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA GA201
GTTS-WQ14184MR IVTScrip™ mRNA-Anti-ANGPT2, REGN-910(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA REGN-910
GTTS-WQ1792MR IVTScrip™ mRNA-Anti-CD19, ADCT-402(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ADCT-402
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW